MA26425A1 - Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number: MA26425A1
Authority: MA; Morocco
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; lactam derivatives; lactam
Prior art date: 1996-03-29

Application number

MA24535A

Other languages

English (en)

Inventor

R Howard Harry

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-29

Filing date

1997-03-26

Publication date

2004-12-20

1997-03-26 Application filed by Pfizer filed Critical Pfizer

2004-12-20 Publication of MA26425A1 publication Critical patent/MA26425A1/fr

Links

150000003951 lactams Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)
Indole Compounds (AREA)
Quinoline Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

MA24535A 1996-03-29 1997-03-26 Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant MA26425A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1513496P	1996-03-29	1996-03-29

Publications (1)

Publication Number	Publication Date
MA26425A1 true MA26425A1 (fr)	2004-12-20

Family

ID=21769713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA24535A MA26425A1 (fr)	1996-03-29	1997-03-26	Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (39)

Country	Link
US (2)	US6462048B2 (fr)
EP (1)	EP0894085B1 (fr)
JP (1)	JP3118467B2 (fr)
KR (1)	KR100305071B1 (fr)
CN (1)	CN1128788C (fr)
AP (1)	AP824A (fr)
AR (1)	AR006390A1 (fr)
AT (1)	ATE302182T1 (fr)
AU (1)	AU706839B2 (fr)
BG (1)	BG64176B1 (fr)
BR (1)	BR9708581A (fr)
CA (1)	CA2249603A1 (fr)
CO (1)	CO4650033A1 (fr)
CZ (1)	CZ293628B6 (fr)
DE (1)	DE69733996T2 (fr)
DZ (1)	DZ2198A1 (fr)
EA (1)	EA001485B1 (fr)
ES (1)	ES2246058T3 (fr)
HN (1)	HN1997000023A (fr)
HR (1)	HRP970175A2 (fr)
HU (1)	HUP9902160A3 (fr)
ID (1)	ID17781A (fr)
IL (1)	IL125377A (fr)
IS (1)	IS4813A (fr)
MA (1)	MA26425A1 (fr)
MY (1)	MY118498A (fr)
NO (1)	NO312957B1 (fr)
NZ (1)	NZ325914A (fr)
OA (1)	OA10879A (fr)
PL (1)	PL329170A1 (fr)
SK (1)	SK131498A3 (fr)
TN (1)	TNSN97056A1 (fr)
TR (1)	TR199801929T2 (fr)
TW (1)	TW413679B (fr)
UA (1)	UA70284C2 (fr)
UY (1)	UY24498A1 (fr)
WO (1)	WO1997036867A1 (fr)
YU (1)	YU11997A (fr)
ZA (1)	ZA972690B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH041367U (fr) *	1990-04-13	1992-01-08
US6906093B2 (en)	1995-06-07	2005-06-14	Sugen, Inc.	Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US6147106A (en)	1997-08-20	2000-11-14	Sugen, Inc.	Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6696448B2 (en) *	1996-06-05	2004-02-24	Sugen, Inc.	3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
UA56185C2 (uk)	1996-09-30	2003-05-15	Пфайзер Інк.	Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) *	1996-09-30	2002-07-23	Pfizer Inc	Aralkyl and aralkylidene heterocyclic lactams and imides
GB9718913D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
US6531502B1 (en)	1998-01-21	2003-03-11	Sugen, Inc.	3-Methylidenyl-2-indolinone modulators of protein kinase
DE19830201A1 (de) *	1998-07-07	2000-01-13	Boehringer Ingelheim Pharma	Mittel mit antidepressiver Wirkung
CA2301899C (fr) *	1998-07-27	2008-11-18	Boehringer Ingelheim Pharma Kg	Agent antidepresseur
US6492398B1 (en)	1999-03-04	2002-12-10	Smithkline Beechman Corporation	Thiazoloindolinone compounds
US6624171B1 (en)	1999-03-04	2003-09-23	Smithkline Beecham Corporation	Substituted aza-oxindole derivatives
GB9904933D0 (en)	1999-03-04	1999-04-28	Glaxo Group Ltd	Compounds
PT1113015E (pt) *	1999-12-29	2004-12-31	Pfizer Prod Inc	Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d
HRP20020751B1 (hr)	2000-02-15	2011-01-31	Sugen	Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
US6620818B1 (en)	2000-03-01	2003-09-16	Smithkline Beecham Corporation	Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
AR042586A1 (es)	2001-02-15	2005-06-29	Sugen Inc	3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JP2005508953A (ja)	2001-10-10	2005-04-07	スージェン・インコーポレーテッド	キナーゼ阻害剤としての３−［４−（置換ヘテロサイクリル）−ピロール−２−イルメチリデン］−２−インドリノン誘導体
PL372096A1 (en)	2002-01-02	2005-07-11	Ardent Pharmaceuticals, Inc.	Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
TWI263497B (en) *	2002-03-29	2006-10-11	Lilly Co Eli	Pyridinoylpiperidines as 5-HT1F agonists
CA2547283C (fr) *	2003-11-26	2010-11-09	Pfizer Products Inc.	Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
BRPI0507190A (pt) *	2004-01-29	2007-06-26	Pfizer Prod Inc	combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores
ES2374629T3 (es)	2004-03-17	2012-02-20	Pfizer Products Incorporated	Nuevos derivados de bencil(iden)-lactama.
WO2005107808A2 (fr) *	2004-05-11	2005-11-17	Pfizer Products Inc.	Combinaison d'antipsychotiques atypiques et d'antagonistes du recepteur de 5-ht1b
CA2567483A1 (fr) *	2004-05-21	2005-12-01	Pfizer Products Inc.	Derives pyrazinylmethyle-lactame
EP1768975A2 (fr) *	2004-06-25	2007-04-04	Pfizer Products Inc.	Pyridyle pipérazines pour le traitement des troubles du snc
ES2371927T3 (es) *	2005-01-13	2012-01-11	Ge Healthcare Limited	Compuestos de bencil-lactama marcados con 11c y su uso como agentes de obtención de imágenes.
WO2006106416A1 (fr) *	2005-04-08	2006-10-12	Pfizer Products Inc.	Pyridil-lactams et leur utilisation comme ligands de recepteurs 5-ht1
US20090286804A1 (en) *	2005-06-17	2009-11-19	Pfizer Inc	Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one as seratonin receptor antagonists
WO2007012964A1 (fr) *	2005-07-25	2007-02-01	Pfizer Products Inc.	Préparation de composés d'alkylpipérazinylphényle par dédoublement classique
WO2007026224A2 (fr) *	2005-08-31	2007-03-08	Pfizer Products Inc.	Composition d'antagoniste 5-ht1b pour le traitement de la depression, de l'anxiete et des troubles de la cognition
WO2007026219A2 (fr) *	2005-08-31	2007-03-08	Pfizer Products Inc.	Composition d'antagonistes du recepteur 5-ht1b servant au traitement d'etats du systeme nerveux central
US20070096411A1 (en) *	2005-11-02	2007-05-03	Rempe Gary L Ii	Device for retaining a kneeling rider on a gliding board
US10154988B2 (en)	2012-11-14	2018-12-18	The Johns Hopkins University	Methods and compositions for treating schizophrenia
MA43313B1 (fr) *	2015-09-02	2022-06-30	Trevena Inc	Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
CN110446495B (zh)	2017-02-17	2023-09-05	特维娜有限公司	含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
CN110520129A (zh)	2017-02-17	2019-11-29	特维娜有限公司	含有5元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
WO2020183011A1 (fr)	2019-03-14	2020-09-17	Institut Curie	Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer
CN116406268A (zh)	2020-10-27	2023-07-07	特维娜有限公司	δ-阿片样物质调节剂的结晶和无定形形式

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4078062A (en) *	1976-10-28	1978-03-07	E. R. Squibb & Sons, Inc.	Substituted 2H-1,4-benzothiazin-3(4H)-ones
JPS62116557A (ja)	1985-11-15	1987-05-28	Takeda Chem Ind Ltd	置換ベンジルラクタム類
US5189179A (en) *	1990-08-29	1993-02-23	Merrell Dow Pharmaceuticals Inc.	Serotonin 5ht1a agonists
ES2162792T3 (es)	1991-09-18	2002-01-16	Glaxo Group Ltd	Derivados de benzanilida como antagonistas de 5-ht1d.
KR100268694B1 (ko)	1991-10-11	2000-10-16	미리암 디. 메코너헤이, 블레어큐. 퍼거슨	레트로바이러스 프로테아제 억제제로 유용한 시클릭 우레아 및 유사체
US5436246A (en) *	1992-09-17	1995-07-25	Merrell Dow Pharmaceuticals Inc.	Serotonin receptor agents
GB9410512D0 (en) *	1994-05-25	1994-07-13	Smithkline Beecham Plc	Novel treatment
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US6467084B1 (en) *	1999-12-16	2002-10-15	Emware, Inc.	Systems and methods for reprogramming an embedded device with program code using relocatable program code

1997
- 1997-02-03 HU HU9902160A patent/HUP9902160A3/hu unknown
- 1997-02-03 ES ES97900717T patent/ES2246058T3/es not_active Expired - Lifetime
- 1997-02-03 TR TR1998/01929T patent/TR199801929T2/xx unknown
- 1997-02-03 US US09/155,215 patent/US6462048B2/en not_active Expired - Fee Related
- 1997-02-03 CA CA002249603A patent/CA2249603A1/fr not_active Abandoned
- 1997-02-03 CZ CZ19983052A patent/CZ293628B6/cs not_active IP Right Cessation
- 1997-02-03 IL IL12537797A patent/IL125377A/xx not_active IP Right Cessation
- 1997-02-03 AU AU13170/97A patent/AU706839B2/en not_active Ceased
- 1997-02-03 EA EA199800771A patent/EA001485B1/ru not_active IP Right Cessation
- 1997-02-03 AT AT97900717T patent/ATE302182T1/de not_active IP Right Cessation
- 1997-02-03 SK SK1314-98A patent/SK131498A3/sk unknown
- 1997-02-03 NZ NZ325914A patent/NZ325914A/en unknown
- 1997-02-03 PL PL97329170A patent/PL329170A1/xx unknown
- 1997-02-03 JP JP09535074A patent/JP3118467B2/ja not_active Expired - Fee Related
- 1997-02-03 CN CN97193251A patent/CN1128788C/zh not_active Expired - Fee Related
- 1997-02-03 WO PCT/IB1997/000076 patent/WO1997036867A1/fr not_active Ceased
- 1997-02-03 BR BR9708581A patent/BR9708581A/pt not_active Application Discontinuation
- 1997-02-03 KR KR1019980707713A patent/KR100305071B1/ko not_active Expired - Fee Related
- 1997-02-03 EP EP97900717A patent/EP0894085B1/fr not_active Expired - Lifetime
- 1997-02-03 DE DE69733996T patent/DE69733996T2/de not_active Expired - Fee Related
- 1997-02-04 TW TW086101295A patent/TW413679B/zh active
- 1997-02-06 HN HN1997000023A patent/HN1997000023A/es unknown
- 1997-03-02 UA UA98095077A patent/UA70284C2/uk unknown
- 1997-03-13 CO CO97013714A patent/CO4650033A1/es unknown
- 1997-03-21 UY UY24498A patent/UY24498A1/es not_active IP Right Cessation
- 1997-03-25 AR ARP970101200A patent/AR006390A1/es not_active Application Discontinuation
- 1997-03-26 MA MA24535A patent/MA26425A1/fr unknown
- 1997-03-26 HR HR60/015,134A patent/HRP970175A2/hr not_active Application Discontinuation
- 1997-03-26 DZ DZ970045A patent/DZ2198A1/fr active
- 1997-03-26 TN TNTNSN97056A patent/TNSN97056A1/fr unknown
- 1997-03-27 AP APAP/P/1997/000955A patent/AP824A/en active
- 1997-03-27 YU YU11997A patent/YU11997A/sh unknown
- 1997-03-27 ID IDP971025A patent/ID17781A/id unknown
- 1997-03-27 ZA ZA972690A patent/ZA972690B/xx unknown
- 1997-03-28 MY MYPI97001340A patent/MY118498A/en unknown
1998
- 1998-07-29 IS IS4813A patent/IS4813A/is unknown
- 1998-09-16 OA OA9800170A patent/OA10879A/en unknown
- 1998-09-24 BG BG102791A patent/BG64176B1/bg unknown
- 1998-09-28 NO NO19984513A patent/NO312957B1/no unknown
2002
- 2002-08-15 US US10/219,692 patent/US6924289B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69733996D1 (de)	2005-09-22
UY24498A1 (es)	2000-09-29
ZA972690B (en)	1998-09-28
BG102791A (en)	1999-11-30
NO984513L (no)	1998-09-28
AU706839B2 (en)	1999-06-24
ATE302182T1 (de)	2005-09-15
TR199801929T2 (xx)	1998-12-21
CO4650033A1 (es)	1998-09-03
AP824A (en)	2000-04-28
TW413679B (en)	2000-12-01
US20030027812A1 (en)	2003-02-06
ID17781A (id)	1998-01-29
CN1214043A (zh)	1999-04-14
DE69733996T2 (de)	2006-07-20
CZ305298A3 (cs)	1999-07-14
HK1019446A1 (en)	2000-02-11
AU1317097A (en)	1997-10-22
EA199800771A1 (ru)	1999-06-24
SK131498A3 (en)	2000-09-12
EA001485B1 (ru)	2001-04-23
PL329170A1 (en)	1999-03-15
NO984513D0 (no)	1998-09-28
KR20000005083A (ko)	2000-01-25
ES2246058T3 (es)	2006-02-01
CN1128788C (zh)	2003-11-26
WO1997036867A1 (fr)	1997-10-09
US20020028821A1 (en)	2002-03-07
IL125377A0 (en)	1999-03-12
AP9700955A0 (en)	1997-04-30
HUP9902160A3 (en)	2001-02-28
BG64176B1 (bg)	2004-03-31
AR006390A1 (es)	1999-08-25
CZ293628B6 (cs)	2004-06-16
US6462048B2 (en)	2002-10-08
NZ325914A (en)	1999-09-29
UA70284C2 (en)	2004-10-15
HUP9902160A2 (hu)	1999-11-29
JPH11506472A (ja)	1999-06-08
HRP970175A2 (en)	1998-12-31
TNSN97056A1 (fr)	2005-03-15
CA2249603A1 (fr)	1997-10-09
OA10879A (en)	2001-10-05
JP3118467B2 (ja)	2000-12-18
BR9708581A (pt)	1999-08-03
US6924289B2 (en)	2005-08-02
KR100305071B1 (ko)	2001-12-12
MY118498A (en)	2004-11-30
EP0894085A1 (fr)	1999-02-03
IS4813A (is)	1998-07-29
EP0894085B1 (fr)	2005-08-17
NO312957B1 (no)	2002-07-22
IL125377A (en)	2005-07-25
HN1997000023A (es)	1997-06-05
YU11997A (sh)	1999-09-27
DZ2198A1 (fr)	2002-12-02

Publication	Publication Date	Title
MA26424A1 (fr)	2004-12-20	Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26433A1 (fr)	2004-12-20	Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26472A1 (fr)	2004-12-20	Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2198A1 (fr)	2002-12-02	Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
MA26468A1 (fr)	2004-12-20	Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26479A1 (fr)	2004-12-20	Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26432A1 (fr)	2004-12-20	Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26559A1 (fr)	2004-12-20	Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26558A1 (fr)	2004-12-20	Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2740136B1 (fr)	1998-01-09	Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
MA26680A1 (fr)	2004-12-20	Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26465A1 (fr)	2004-12-20	Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26438A1 (fr)	2004-12-20	Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2780057B1 (fr)	2002-09-13	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26439A1 (fr)	2004-12-20	Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26499A1 (fr)	2004-12-20	Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
FR2735777B1 (fr)	1997-09-12	Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
MA26687A1 (fr)	2004-12-20	4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26414A1 (fr)	2004-12-20	Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant.
MA23831A1 (fr)	1996-10-01	Derives de quinazoline, procede pour leur preparation et composition les contenant
MA26471A1 (fr)	2004-12-20	Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26505A1 (fr)	2004-12-20	Derives de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26526A1 (fr)	2004-12-20	Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2751334B1 (fr)	1998-10-16	Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant